ATE212233T1 - Impfstoffe gegen neisseria meningitidis gruppe c - Google Patents

Impfstoffe gegen neisseria meningitidis gruppe c

Info

Publication number
ATE212233T1
ATE212233T1 AT93921251T AT93921251T ATE212233T1 AT E212233 T1 ATE212233 T1 AT E212233T1 AT 93921251 T AT93921251 T AT 93921251T AT 93921251 T AT93921251 T AT 93921251T AT E212233 T1 ATE212233 T1 AT E212233T1
Authority
AT
Austria
Prior art keywords
gcmp
conjugate
modified
neisseria meningitidis
vaccines against
Prior art date
Application number
AT93921251T
Other languages
English (en)
Inventor
Francis Michon
Harold Jennings
Joseph Y Tai
Lucjan J J Hronowski
Sharon Mates
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/938,367 external-priority patent/US5425946A/en
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of ATE212233T1 publication Critical patent/ATE212233T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT93921251T 1992-08-31 1993-08-30 Impfstoffe gegen neisseria meningitidis gruppe c ATE212233T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/938,367 US5425946A (en) 1992-08-31 1992-08-31 Vaccines against group C Neisseria meningitidis
US6450193A 1993-05-19 1993-05-19
PCT/US1993/008155 WO1994005325A1 (en) 1992-08-31 1993-08-30 Vaccines against group c neisseria meningitidis

Publications (1)

Publication Number Publication Date
ATE212233T1 true ATE212233T1 (de) 2002-02-15

Family

ID=26744584

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921251T ATE212233T1 (de) 1992-08-31 1993-08-30 Impfstoffe gegen neisseria meningitidis gruppe c

Country Status (12)

Country Link
EP (1) EP0658118B1 (de)
JP (2) JP4097691B2 (de)
AT (1) ATE212233T1 (de)
AU (1) AU4841693A (de)
CA (1) CA2142981C (de)
DE (1) DE69331495T2 (de)
DK (1) DK0658118T3 (de)
ES (1) ES2171418T3 (de)
NO (1) NO323616B1 (de)
PL (1) PL175595B1 (de)
PT (1) PT658118E (de)
WO (1) WO1994005325A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
GB9713156D0 (en) * 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0994723A1 (de) * 1997-06-24 2000-04-26 Chiron Corporation Verfahren um erwachsenen mit anti-meningokokken impfstoffzusammensetzungen zu immunizieren
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
AU2001253568A1 (en) * 2000-04-18 2001-10-30 Dan C. Deborde Lipopolysaccharide-conjugate vaccine for sepsis treatment
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
KR101266552B1 (ko) * 2003-06-23 2013-05-23 박스터 헬쓰케어 에스.에이. 그룹 ｙ 수막염균에 대한 백신 및 그의 수막염균성 조합
ES2397923T3 (es) 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
NZ572054A (en) 2006-03-22 2011-12-22 Novartis Ag Regimens for immunisation with meningococcal conjugates
IN2009KN04098A (de) 2007-06-04 2015-08-28 Novartis Ag
HRP20120433T1 (en) 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
CA2746942A1 (en) * 2008-12-22 2010-07-01 Children's Hospital & Research Center At Oakland Ex-vivo passive protection bacteremia assay
EP3017826A1 (de) 2009-03-24 2016-05-11 Novartis AG Kombinationen von meningokkoken-faktor-h-bindenden proteinen und pneumokokken-saccharid-konjugaten
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
EP2797624A1 (de) 2011-12-29 2014-11-05 Novartis AG Kombinationen aus meningokokken-faktor-h-bindenden proteinen
EP2822584A1 (de) 2012-03-08 2015-01-14 Novartis AG Kombinationsimpfstoffe mit tlr4-agonisten
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
KR20160040556A (ko) 2013-07-11 2016-04-14 노파르티스 아게 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
JP7104027B2 (ja) 2016-09-02 2022-07-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 淋菌に対するワクチン
CN109890413B (zh) * 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 脑膜炎奈瑟氏菌疫苗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5097020A (en) * 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.

Also Published As

Publication number Publication date
DE69331495D1 (de) 2002-03-14
NO950739D0 (no) 1995-02-27
EP0658118B1 (de) 2002-01-23
JPH08500607A (ja) 1996-01-23
EP0658118A4 (de) 1995-09-13
AU4841693A (en) 1994-03-29
DE69331495T2 (de) 2002-10-31
DK0658118T3 (da) 2002-05-06
JP2008044955A (ja) 2008-02-28
CA2142981A1 (en) 1994-03-17
PT658118E (pt) 2002-05-31
NO323616B1 (no) 2007-06-18
WO1994005325A1 (en) 1994-03-17
PL307745A1 (en) 1995-06-12
CA2142981C (en) 2007-10-23
JP4097691B2 (ja) 2008-06-11
NO950739L (no) 1995-04-26
EP0658118A1 (de) 1995-06-21
ES2171418T3 (es) 2002-09-16
PL175595B1 (pl) 1999-01-29

Similar Documents

Publication Publication Date Title
DE69331495D1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
Schneerson et al. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates
ES8707861A1 (es) Un metodo para preparar un conjugado inmunogeno
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
FI912965A0 (fi) Vaccin innehaollande protein fraon klass 1-yttermembranen av meningokocker.
DK0778781T3 (da) Pneumokok-polysaccharid-rekombinant pneumolysin-konjugat-vacciner til immunisering mod pneumokokinfektioner
RU2009134033A (ru) Жидкие вакцины для множественных серогрупп менингококков
NO932102L (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
AU570405B2 (en) Conjugates of muramyl-peptides and haptenes
ATE390933T1 (de) Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
ATE529130T1 (de) Trockenformulierung für transkutane immunisierung
DK0994721T3 (da) Nervevækstfaktor som vaccineadjuvans
NZ309713A (en) Oligosaccharides of S pneumoniae serotype 8 and their use in a vaccine
DK341679A (da) Vaccine mod streptokokker og fremgangsmaade til fremstilling deraf
Klipstein et al. Immunological interrelationships between cholera toxin and the heat-labile and heat-stable enterotoxins of coliform bacteria
IL107387A (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
RU93048161A (ru) Комбинированная педиатрическая вакцина с усиленной иммуногенностью каждого вакционного компонента
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
Schneerson et al. Semi-Synthetic Vaccines Composed of Capsular Polysaccharides of Pathogenic Bacteria Covalently
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
SHAMS et al. The effect of conjugation on immunogenicity and potency of protein carriers of polyribosylribitol phosphate (PRP) conjugated vaccines in the mouse model
Paniagua-Solis et al. Predicted epitopes of Salmonella typhi OmpC porin are exposed on the bacterial surface
Tai et al. Vaccines against group C neisseria meningitidis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification